Nomura Securities Maintains a 'Buy' on Danaher (DHR); Premier, Through-the-Cycle Stock

Nomura Securities maintains a 'Buy' on Danaher (NYSE: DHR) price target of $65.00.

Analyst, Shannon O’Callaghan, said, "Danaher’s success with AB SCIEX (acquired February 2010) demonstrates that the company knows how to win with Life Sciences instrument businesses. While recent cyclical pressures in Tek Instruments and Motion have driven investor criticism of organic growth (only 1.5% in 1Q), we view those dynamics as temporary. Since acquisition, AB SCIEX has seen significant improvements in organic growth, gross margins, operating margins, and new product development."

For an analyst ratings summary and ratings history on Danaher click here. For more ratings news on Danaher click here.

Shares of Danaher closed at $51.89 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)